Remicade is a biologic drug classified as a tumor necrosis factor (TNF) inhibitor [1]. It is also known as infliximab [2].
What other conditions does Remicade treat?
Remicade is approved to treat several inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis [1].
How do TNF inhibitors like Remicade work?
Tumor necrosis factor-alpha (TNF-α) is a protein that plays a significant role in inflammation. In certain autoimmune diseases, the body produces too much TNF-α, leading to inflammation and damage to tissues. Remicade works by binding to TNF-α, preventing it from attaching to its receptors on cells and thereby reducing inflammation [1].
When does Remicade's patent expire?
The original patents for Remicade have expired, allowing for the development of biosimilars [3]. Information on specific patent expiry dates for related intellectual property can be found on DrugPatentWatch.com [4].
What are the available biosimilars for Remicade?
Several biosimilar versions of infliximab are available, including Inflectra (infliximab-dyyb), Renflexis (infliximab-abda), and Ixifi (infliximab-qww) [2]. Biosimilars are approved based on demonstrated similarity to the reference product in terms of safety, purity, and potency [5].
What is the difference between a biosimilar and a generic drug?
Biosimilars are for biologic drugs, which are complex molecules typically derived from living cells. Generic drugs, on the other hand, are for small-molecule drugs and are exact copies of the original drug [5]. Due to the complexity of biologics, biosimilars are not identical to the reference product but are highly similar, with no clinically meaningful differences [5].
What are the risks associated with Remicade treatment?
Remicade, like other TNF inhibitors, can increase the risk of serious infections, including tuberculosis and fungal infections [1]. It may also increase the risk of certain cancers [1]. Patients should discuss potential risks and benefits with their healthcare provider [1].
Can patients switch between Remicade and its biosimilars?
Switching between a reference biologic and its biosimilar is a decision made in consultation with a healthcare provider. While biosimilars are highly similar, the impact of switching on treatment outcomes is a consideration for physicians and patients [5].
Sources:
[1] https://www.remicade.com/
[2] https://www.fda.gov/drugs/information-drug-product-quality/reference-lists-approved-drug-products-reference-listed-drug-rls
[3] https://www.criver.com/capabilities/biologics-development/biosimilars
[4] https://drugpatentwatch.com/
[5] https://www.fda.gov/drugs/biosimilars/biosimilar-product-overview